Compare AbCellera Biologics Inc (ABCL) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Vanguard Real Estate Index Fund ETF — how do they compare? AbCellera Biologics Inc trades at $10.26 (market cap $2.99B), while Vanguard Real Estate Index Fund ETF trades at $97.17. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Vanguard Real Estate Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | VNQ | |
|---|---|---|
Market Cap | $2.99B | — |
Sector | Health | — |
52-Week High | $9.76 | $100.95 |
52-Week Low | $2.78 | $87.00 |
Enterprise Value | $2.58B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.
The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.
VNQ, the Vanguard Real Estate ETF, trades at $97.13, up 0.02% on the day, with a bearish technical signal driven by moving averages and neutral oscillators. The ETF offers a dividend of $0.86 scheduled for June 2026, but key valuation ratios like P/E and P/B are unavailable. Recent news highlights institutional selling and comparisons with global real estate ETFs, emphasizing VNQ's U.S. REIT focus and low fees.
Outlook: VNQ faces headwinds from bearish technicals and institutional outflows, but its low expense ratio and U.S. real estate exposure provide stability. Risks include interest rate sensitivity and underperformance versus broader markets, as noted in long-term return comparisons. Investors should weigh dividend income against sector volatility and macroeconomic factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
